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Fusion genes are hallmarks of various cancer types and important determinants for diagnosis,
prognosis and treatment. Fusion gene partner choice and breakpoint-position promiscuity
restricts diagnostic detection, even for known and recurrent configurations. Here, we develop
FUDGE (FUsion Detection from Gene Enrichment) to accurately and impartially identify
fusions. FUDGE couples target-selected and strand-specific CRISPR-Cas9 activity for fusion
gene driver enrichment— without prior knowledge of fusion partner or breakpoint-location—
to long read nanopore sequencing with the bioinformatics pipeline NanoFG. FUDGE has
flexible target-loci choices and enables multiplexed enrichment for simultaneous analysis of
several genes in multiple samples in one sequencing run. We observe on-average 665 fold
breakpoint-site enrichment and identify nucleotide resolution fusion breakpoints within
2 days. The assay identifies cancer cell line and tumor sample fusions irrespective of partner
gene or breakpoint-position. FUDGE is a rapid and versatile fusion detection assay for
diagnostic pan-cancer fusion detection.
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Fusion genes are hallmarks of many human cancers. Recentstudies suggest that up to 16% of cancers are driven by afusion gene1. Some cancer types, such as prostate cancer or
chronic myeloid leukemia (CML), are characterized by a specific
fusion gene (TMPRSS2-ERG and BCR-ABL1, respectively),
whereas other cancer types do not show such clear associations1,2.
Most fusion genes are highly variable with respect to fusion gene
configurations and exact breakpoint-locations. Often, one gene is
a recurrent fusion partner (e.g., KMT2A/MLL, ALK) which
exhibits a tissue-specific pattern3. However, these genes can fuse
to a multitude of partners to obtain their oncogenic potential.
One striking example is KMT2A, formerly known as MLL, which
is a prominent fusion partner in pediatric acute myeloid leukemia
(AML) and the predominant fusion partner in acute lymphocytic
leukemia (ALL) diagnosed in infants (i.e., children <1 year of
age), and has been reported with more than 130 different gene
configurations4,5.
Whereas fusion detection is pathognomonic for some cancer
types, it is a determinant of prognosis or treatment choices in
other cancer types6,7. However, the high levels of variability in
fusion gene configurations drastically limits diagnostic detection.
Current diagnostic strategies include (break-apart) Fluorescence
In Situ Hybridization (FISH) and reverse transcription quanti-
tative polymerase chain reaction (RT-qPCR) assays, depending
on the knowledge and breakpoint-variability of the fusion part-
ner7. However, these assays are laborious and time-consuming
and may not identify the fusion partner. Recently, next generation
sequencing (NGS) assays which specifically target recurrent
fusion partners have been developed and are currently imple-
mented in clinical practice8,9. These assays are highly versatile
with respect to partner identification and input material (e.g.,
suitable for DNA isolated from Formalin-Fixed Paraffin
Embedded tissue blocks; FFPE), but are accompanied with longer
turnaround-times, increased costs and bioinformatic challenges.
Recent long read sequencing technologies such as Oxford
Nanopore Technology (ONT) sequencing have proven immen-
sely helpful in elucidating structural variation in human gen-
omes10. Furthermore, the real-time sequencing capabilities yield
abundant opportunities for clinical applications. However,
sequencing throughput from one nanopore flow cell (2–5x gen-
ome coverage; R9.4) is insufficient to elucidate the complete
structural variation (SV) landscape of a genome11. ONT recently
released a Cas9-based protocol for enrichment of specific geno-
mic regions, which utilizes the upstream (5′) and downstream (3′)
flanking sequences of the region of interest (ROI), to excise the
latter and perform targeted sequencing12. Two publications have
utilized this method to study methylation and structural var-
iants12, as well as genome duplications13. With this technique, a
median on-target coverage of 165x and 254x was achieved,
respectively, offering a unique tool to sequence SVs such as fusion
genes. However, this approach requires knowledge of both
flanking sequences of the ROI, which again restricts its applica-
tion to detection of only known fusion gene partner
combinations.
We here develop FUDGE (FUsion Detection from Gene
Enrichment) as a fusion gene identification strategy to perform
targeted enrichment of fusion genes and identify — without prior
knowledge — the unknown fusion partner and precise breakpoint
by using long read, real-time ONT sequencing. Furthermore, we
create and implement a complementary bioinformatic tool,
NanoFG, to detect fusion genes from long read nanopore
sequencing data. Utilizing this approach, we achieve an average
breakpoint-spanning coverage of 68x — resulting in an average
enrichment of 665x — and identify fusion gene partners from
various cancer types (e.g., AML, Ewing Sarcoma, Colon) within
48 h. In addition, we offer strategies for low-input DNA samples
(10 ng), as well as multiplexing of samples and targets to mini-
mize assay costs. Finally, we utilize this method on material in
which routine diagnostic procedures were unable to detect the
fusion partner, and identify the fusion partner within two days.
Results
Schematic overview of fusion gene detection assay. We devel-
oped FUDGE to specifically enrich for fusion genes in which only
one gene partner is known and for which the other fusion gene
partner and/or breakpoint is unknown. To achieve this, genomic
DNA isolated from fresh frozen samples is dephosphorylated as
previously described12 and a crRNA flanking the suspected
breakpoint region(s) is utilized to target Cas9 to a specific
genomic loci where it creates a double-strand DNA break
(Fig. 1a). The Cas9 protein stays predominantly bound to the
PAM-distal side of the cut, therefore masking the phosphoryla-
tion side on this end, while exposing phosphorylated DNA on the
PAM-proximal side of the cut (Fig. 1b). This phosphorylated
DNA, following dA-tailing, creates a distinct contact-point that
can be used to anneal the ONT-specific sequencing adapters —
specifically to this region only. To achieve directionality, the
crRNAs are designed in a strand-directed manner to specifically
direct reads upstream or downstream of the crRNA sequence —
effectively sequencing into the suspected 5′ or 3′ fusion partner
(Fig. 1b, Methods, and Supplementary Fig. 1). Thereafter, the
enriched libraries are sequenced on one ONT flow cell (R9.4). To
robustly detect fusion genes from low coverage nanopore
sequencing data, we developed a bioinformatic tool, NanoFG,
which reports fusion partners, exact breakpoint-locations, the
breakpoint-sequence and primers for validation purposes
(Fig. 1c).
Enrichment and directed sequencing. To test the ability of the
fusion gene detection assay to generate sufficient enrichment and
to direct reads in the desired direction, we applied FUDGE to
genomic DNA from a male healthy donor. As a proof-of-
principle we designed crRNAs for a panel of recurrent fusion
partner genes (BRAF, EWSR1, and SS18) in a strand-specific
manner. We performed two separate library preparations (PP1
and PP2) and targeted two different exons for each of the three
genomic loci per library (Fig. 2a and Supplementary Data 1). As a
positive control, we targeted two genomic loci (C9orf72 and
FMR1) for which we previously performed targeted sequencing,
and used two crRNAs flanking the ROI and with each targeting
one of the two different strands (Fig. 2a and Supplementary
Data 1). After the sample processing, libraries of PP1 and PP2
were pooled and sequenced on a single flow cell. Sequencing
resulted in a throughput of 1.665 Gbs which corresponds to a
mean genome coverage of 0.5x (Supplementary Data 1). For the
loci where only one strand of the genome was targeted, on
average 89% of the reads sequenced in the anticipated 5′ or 3′
direction (Fig. 2b–d and Supplementary Fig. 2a–e). The coverage
at the PP1 and PP2 cut-sites were 115x and 102x (BRAF)
(Fig. 2b), 142x and 101x (EWSR1) (Fig. 2c), 117x and 118x (SS18)
(Fig. 2d), 57x and 104x (C9orf72) (Fig. 2e), and 11x and 44x
(FMR1) (Fig. 2f), respectively. The average read-length was 9.9 kb
(Fig. 2g and Supplementary Data 1) and on average 116 reads
crossed the most common fusion breakpoint-locations (Fig. 2b–d
and Supplementary Data 1), proving the applicability of this assay
to detect fusion genes irrespective of breakpoint-position.
Identification of gene fusions in cancer cell lines. To test that
FUDGE identifies fusion genes independent of targeted gene or
breakpoint-location, we applied this technique to three fusion-
positive cancer cell lines in which the fusion configuration was
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previously identified. The Ewing sarcoma cell lines A4573 (ref. 14)
and CHP-100 (ref. 15) harbor the EWSR1-FLI1 fusion gene and
the synovial sarcoma HS-SYII cell line contains a SS18-SSX1
fusion16. We targeted three loci per sample (BRAF Exon 10,
EWSR1 Exon 7, SS18 Exon 9) and sequenced the samples on one
flow cell each (Supplementary Data 1). This produced a mean
genome coverage of 0.24x (A4573), 0.15x (CHP-100), and 0.015x
(HS-SYII) (Fig. 3a). We observed a sharp increase to 81x (A4573),
66x (CHP-100), and 11x (HS-SYII) on-target coverage (cut to
breakpoint) due to the achieved directionality (Fig. 3a and Sup-
plementary Fig. 1). This relates to an overall on-target fold-
enrichment of 342x (A4573), 443x (CHP-100), and 735x (HS-
SYII) (Fig. 3b–e).
To easily identify fusion-spanning reads from nanopore data,
we developed NanoFG17. NanoFG is an amendment to
NanoSV10 that calls fusion genes from nanopore sequencing
data and reports the exact breakpoint-location, breakpoint-
sequence and breakpoint-spanning primers for each gene fusion
(Fig. 1). The breakpoint was spanned by 69 (A4573), 62 (CHP),
and 6 (HS-SYII) reads, which correlates to a 290x, 417x, and 406x
enrichment, respectively. NanoFG identified the two EWSR1-
FLI1 fusion genes with 28 (A4573) (Fig. 3a, c) and 18 (CHP-100)
(Fig. 3a, d) fusion-spanning reads which relates to a fusion-
specific enrichment of 118x and 121x, respectively (Fig. 3b). The
two Ewing sarcoma cell lines harbored the same fusion gene,
however, with different breakpoint-locations (Supplementary
Fig. 3A). These differences were readily detected by NanoFG
and emphasizes the flexibility of this assay to identify fusions
without knowledge of the exact breakpoint-positions. To uncover
why NanoFG did not identify the SS18-SSX1 fusion gene, we
manually investigated the candidate locus in the IGV Browser18.
The sequencing of the HS-SYII cell line resulted in very little
throughput, on-target coverage (11x) (Fig. 3a) and relatively low
breakpoint-spanning reads (6). As a result, only one fusion-
spanning read was produced, which is below the filtering cut-off
for fusion-supporting reads set for NanoFG (requirement of
minimal two fusion-supporting reads). When adjusting the
settings of NanoFG to one supporting read, the SS18-SSX1 fusion
was called (Fig. 3a, e), however, lowering the threshold of fusion-
supporting reads requires manual validation if the fusion status is
unknown to exclude false-positives (Supplementary Fig. 3B).
Despite the low-throughput for the HS-SYII cell line, the assay
resulted in a 68x fusion-specific fold-enrichment (Fig. 3b). This
shows the ability of FUDGE to identify fusion genes irrespective
of fusion partner or breakpoint-location from low-coverage
nanopore sequencing data.
Detection of fusion genes from tumor material. To validate that
FUDGE identifies fusion genes from tumor material and without
prior knowledge of the breakpoint-location, we applied the assay
to six tumor samples of different origins with known fusion
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status. We tested DNA isolated from an Ewing sarcoma (ES1), a
rhabdomyosarcoma (RH), a chronic myeloid leukemia (CML), a
Burkitt’s Lymphoma (BL), a philadelphia chromosome-positive
B-lymphoblastic acute leukemia (B-ALL)(ALL1) and a B-ALL
(ALL2). Rhabdomyosarcomas are characterized by breaks in the
second intron of FOXO1 (104 kb) which then fuses to either
PAX3 or PAX7 (ref. 19). Due to the large potential breakpoint
region within FOXO1, we chose to target the PAX3 and PAX7
genes instead to minimize the number of necessary crRNAs.
Here, the most common breakpoint areas span a 18 kb and 32 kb
region, respectively. Therefore, we designed sequential crRNAs to
span the potential breakpoint regions of both genes (Supple-
mentary Data 1). The CML and the ALL1 harbored a BCR-ABL1
fusion gene with unknown breakpoint position. The BCR gene
harbors three recurrent breakpoint clusters, spanning 6.6 kb
between exon 12 and exon 15 (major-cluster), 71 kb between
exon 1 and exon 2 (minor-cluster), and 1.3 kb between exon 19
and exon 20 (micro-cluster). To comprehensively cover all pos-
sible breakpoints, we targeted all three clusters with in total eleven
crRNAs (Supplementary Data 1). We sequenced each tumor
sample on a single flow cell and identified, as expected, an
EWSR1-FLI1 fusion (ES1, 8 reads) (Supplementary Data 1 and
Supplementary Figs. 3A and 4A), a PAX3-FOXO1 fusion (RH, 32
reads) (Fig. 4a, d), a BCR-ABL1 fusion within the major-cluster
(CML, 22 reads) (Fig. 4b, d), a translocation between MYC and
the IGH locus (BL, 3 reads) (Fig. 4d and Supplementary Fig. 4B),
a BCR-ABL1 fusion within the minor-cluster (ALL1, 27 reads)
(Fig. 4d and Supplementary Fig. 4C) and a CRLF2-P2RY8 rear-
rangement (ALL2, 185 reads) (Fig. 4c, d). The on-target enrich-
ment was 498x (ES1), 930x (RH1), 611x (CML), 347x (BL), 679
(ALL1), and 3492 (ALL2) and the breakpoint-spanning enrich-
ment was 406x (ES1), 838x (RH1), 598x (CML), 81x (BL), 633x
(ALL1), and 3601x (ALL2) (Fig. 4e). From this, a fusion-specific
enrichment of 270x (ES1), 258x (RH1), 188x (CML), 61x (BL),
197x (ALL1), and 3382x (ALL2) was achieved (Fig. 4e). Fur-
thermore, we identified two additional fusion events, a reciprocal
FOXO1-PAX3 (RH2) fusion with eight fusion-supporting reads
for the RH sample and a DRICH1-BCR (CML2) fusion with three
fusion-supporting reads for the CML sample. As these events
were unexpected findings, we validated them by breakpoint PCR
(Supplementary Fig. 5A, B). We furthermore performed Sanger
validation on the DRICH1-BCR fusion, as this event has not been
previously reported in literature (Supplementary Fig. 5C). It is
important to note that NanoFG is specifically designed to detect
fusion genes with breakpoints within both of the involved fusion
partners. As the IGH/MYC translocation (IGH-breakpoint
approximatively 2.5 kb upstream of IGHM) and CRLF2-P2RY8
rearrangement (CRLF2-breakpoint approximatively 3.5 kb
upstream of CRLF2) do not meet this criterium, NanoFG does
not report them and the use of NanoSV is more appropriate. For
instances where a fusion event is expected in areas outside of
annotated genes (including promoter, both UTRs, and exonic/
intronic regions), manual analysis of the variant calling file (vcf)
reported by NanoSV, an initial step in the NanoFG pipeline
(Methods) is required. Here, the information on exact breakpoint
position, number of supporting reads, etc. can be extracted.
In summary, this demonstrates the ability of FUDGE to detect
known and reciprocal fusion genes and genomic rearrangements
from patient samples irrespective of tumor type.
Blinded fusion gene detection and run time analysis. To con-
firm that FUDGE identifies fusion genes without prior knowledge
of fusion partner or fusion status, we tested two tumor samples in
a blinded manner (B1 and B2). For the B1 sample, diagnostic
efforts identified a KMT2A fusion through break-apart FISH;
however, the fusion partner could not be identified and was
unknown prior to the experiment described here. The KMT2A
gene is a frequent fusion partner in AML and ALL and shows two
major breakpoint clusters4 of which we designed crRNAs for both
(Supplementary Data 1). The B2 sample was randomly chosen
out of a pool of six tumor samples (four ALL, one BL, one
Burkitt’s-ALL) which could potentially harbor a BCR-ABL1, IGH/
MYC, or CRLF2-P2RY8 rearrangement. Therefore, we targeted
the B1 sample with two crRNAs and the B2 sample with 14
crRNAs (Supplementary Data 1) and sequenced both samples on
one flow cell each. NanoFG identified a KMT2A-MLLT6 fusion in
B1 (Fig. 5a) and a BCR-ABL1 fusion in B2 (Fig. 5b) with 29
fusion-spanning and 27 fusion-spanning reads, respectively
(Fig. 5c). Overall, we observed a breakpoint-spanning enrichment
of 938x (B1) and 313x (B2) and a fusion-spanning enrichment of
143x (B1) and 148x (B2) (Fig. 5d). This demonstrates the capacity
of FUDGE to identify unknown fusion events from tumor
material.
Furthermore, we performed a retrospective time-course
experiment on all eight sequenced tumor samples to identify
the necessary sequencing time to detect fusion-spanning reads
(Fig. 5e, f). On-average, 70% of the fusion-spanning reads were
produced within the first 12 h of sequencing and 90% of the
fusion-spanning reads were produced within the first 24 h of
sequencing (Fig. 5e). For all samples, except the IGH/MYC
rearrangement in BL, it took less than three hours of sequencing
time to identify two fusion-spanning read (Fig. 5f). This
highlights the speed of our approach and indicates that
if sequencing would be stopped after 24 h, the majority of
fusion-spanning reads could be obtained.
Fusion gene detection from low input tumor material. The
amount of available tumor material is often a limiting factor for
genomic analysis. To circumvent this problem, we tested if our
pipeline was compatible with whole genome amplified (WGA)
material. WGA produces DNA fragments of considerable length
(up to 100 kb)20, and could therefore be a suitable method to
produce enough DNA at sufficient length for targeted nanopore
sequencing. Therefore, we sequenced WGA-DNA of two colon
cancer samples (C1 and C2), known to harbor BRAF fusions
(AGAP3-BRAF and TRIM24-BRAF, respectively)21, a sarcoma
sample with a SS18-SSX1 fusion (S1) and a PDX sarcoma sample
with unknown fusion status (S2). We targeted the S2 sample with
nine crRNAs targeting the most common recurrent sarcoma
fusion partners EWSR1, PAX3, PAX7, and SS18. For all samples
we performed WGA on 10 ng starting material and subjected 1 μg
of WGA-DNA to the enrichment protocol. Genome coverage
(Fig. 6a) and read-length were comparable to previous experi-
ments (Supplementary Data 1). Initially NanoFG did not detect
the AGAP3-BRAF fusion, however, lowering the threshold to one
fusion-supporting read identified the fusion gene (Fig. 6a–c). The
TRIM24-BRAF fusion was called by NanoFG with eleven fusion-
spanning reads (Fig. 6a, b, d). For the S1 and the S2 sample,
neither NanoFG nor manual inspection in IGV could detect a
targeted fusion gene. Notably, WGA introduced accompanying
structural variation leading to a high number of fusion gene
predictions (Supplementary Fig. 5D) and difficulties for manual
inspection in IGV. However, we show that a fusion supporting
threshold of two reads is a reasonable cut-off for normal and
WGA-samples, as the number of predicted fusions decreases
drastically compared to one supporting read but remains rela-
tively stable compared to a higher fusion-support (Supplementary
Fig. 5D). Furthermore, fusion genes identified by NanoFG that
were not targeted through crRNAs within our assay are very
likely to be false-positives. We successfully validated the two
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BRAF fusion genes, detected by a single fusion-spanning read
(such as in AGAP3-BRAF), by utilizing the exact breakpoint-
locations provided by NanoFG and breakpoint-spanning PCR on
the non-amplified tumor DNA (Supplementary Fig. 5E). In
addition, for the BRAF fusions, the breakpoint junction locations
were 6.5 kb apart (Fig. 6c, d and Supplementary Fig. 3), high-
lighting the unbiased performance of our assay. This demon-
strates that FUDGE may be successfully applied to WGA material
and NanoFG still accurately identifies the exact genomic break-
point of the structural variants; however, prior knowledge of both
fusion genes is required.
Multiplexing of fusion positive cell lines. Parallel identification
and cost-reduction are key for diagnostic approaches. Therefore,
we tested the feasibility to multiplex samples in one sequencing
run. We obtained DNA from four KMT2A-fusion positive cell
lines (ALLPO, KOPN8, ML2 and Monomac-1) with different
fusion partners (MLLT1, MLLT2, MLLT3, and MLLT4). We used
two crRNAs targeting both breakpoint clusters (Supplementary
Table. 1) and produced separate libraries for each sample
(Fig. 7a). The targeted libraries were pooled pre-sequencing
without barcoding and run on a single flow cell. This multiplexing
approach resulted in a genome coverage of 0.57x and average
read-length of 9.2 kb (Supplementary Data 1). NanoFG identified
the four different fusion partners (Supplementary Fig. 6A) and 6
different breakpoint-locations (Fig. 7b). Interestingly, two
KMT2A-fusions (MLLT2 and MLLT3) appeared to be reciprocal
(Supplementary Fig. 6A, B). The breakpoints within KMT2A
spanned a region of 6 kb, and we identified breakpoints for
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reciprocal fusions to be location-independent (Fig. 7c). We uti-
lized the breakpoint-spanning primers and tested all samples for
the occurrence of all fusion genes (Fig. 7a). This approach easily
deconvoluted the sample-of-origin of each fusion, therefore
validating this multiplexing approach (Supplementary Fig. 7A).
Of note, the Monomac-1 cell line (KMT2A-MLLT3) also exhib-
ited a positive result for the KMT2A-MLLT1 fusion. This could be
traced back to a contamination in the cultured cell line, high-
lighting the sensitivity of this assay to detect subclonal events. We
isolated fresh DNA from the Monomac-1 cell line and could
indeed only validate the expected fusion gene KMT2A-MLLT3
(Supplementary Fig. 7B). Furthermore, from the coverage plot we
observed 26 reads within the MLLT4 fusion partner (Supple-
mentary Fig. 6A) which were not explained by any of the NanoFG
detected fusions. Upon manual investigation in the IGV browser,
we identified one fusion, KMT2A-MLLT4, that had a more
complex rearrangement which was not called by NanoFG (Sup-
plementary Fig. 7C). In this case, a small 30 bp region of KMT2A
was deleted, followed by a 185 bp inversion and the ultimate
fusion to MLLT4. We again designed breakpoint-spanning pri-
mers and in addition, performed Sanger-sequencing on the
amplicons and validated the occurrence and structure of the
complex rearrangement (Supplementary Fig. 7C). As a result,
with the use of only one nanopore flow cell, we identified seven
fusion genes from four samples with a collective on-target
enrichment of 349x resulting in an average of 18 fusion-spanning
reads (Fig. 7d). This shows the ability of our approach to mul-
tiplex samples with different fusion genes and breakpoint-
positions and pinpoint the sample-of-origin by a simple PCR
assay.
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Discussion
Fusion genes are critical determinants for diagnosis, prognosis and
treatment opportunities for various cancer types22. However,
fusion gene detection by diagnostic approaches is limited to highly
recurrent fusion gene configurations. We here developed FUDGE,
a fusion detection assay from gene enrichment coupled to nano-
pore sequencing, which enables rapid partner-location and
breakpoint-location independent fusion gene detection within 48 h.
Rapid identification of the genomic breakpoint offers the
opportunity to utilize the breakpoint junctions as a biomarker for
minimal residual disease (MRD) tracing23. Common diagnostic
approaches for fusion gene detection can be divided into DNA or
RNA-based approaches (Table 1). Detection of fusion genes on
the RNA level might be less complex due to the restriction of
breakpoints to exon-exon junctions; however, RNA molecules are
less stable and the overall abundance is influenced by expression
levels. DNA-based approaches such as targeted NGS assays or
WGS are preferable since they identify all fusion gene events
including promoter fusions, as well as the exact genomic break-
point. However, these assays are hampered by longer turn-around
times and WGS can result in high false-positive rates.
With FUDGE we offer fast and unbiased fusion gene detection.
We successfully identified fusion genes from genomic DNA
independent of cancer type or fusion gene configuration and/or
breakpoint-positions. We targeted ten recurrent fusion partners
within eight solid and hematological tumor specimens and
identified 22 unique fusion gene configurations, highlighting the
complexity of fusion gene biology. In one case, KMT2A was
identified as a fusion partner by break-apart FISH through
diagnostic efforts; however, the fusion partner was undetectable.
We applied FUDGE to the sample and identified MLLT6 as the
fusion partner within two days (provided the crRNA was already
designed and in-house). Furthermore, FUDGE also detects reci-
procal fusion events without additional efforts. In the case of two
BRAF fusion-positive samples, the breakpoint locations were >6
kb apart from each other. Conventional methods such as qPCR
would have not sufficed to span this large region of possible
breakpoint-positions. We integrated an adaptation to the protocol
to design sequential guides, offering the opportunity to span large
regions of possible breakpoint-locations. For the BCR-ABL1
fusion, we spanned a >80 kb region, highlighting the versatility
of FUDGE.
With our assay, fusion detection is possible within 48 h. Rapid
identification of fusion genes is essential for tumor types where
fusion genes are pathognomonic such as Ewing sarcoma or
synovial sarcoma22,24. Hence, early detection allows for early
definitive diagnosis and treatment initiation. Furthermore,
occurrence of a specific fusion gene configuration can be a
determinant of prognosis25. FUDGE identified all fusion gene
configurations within 48 h, allowing immediate diagnosis and
treatment initiation. In addition, we show that 70% of the fusion-
supporting reads are produced in the first 12 h of sequencing and
that three hours of sequencing are sufficient to identify two
fusion-spanning reads, offering the opportunity to reduce the
assay time for urgent cases to less than a day. Until now, we
focused our assay on ten different recurrent fusion genes; how-
ever, expanding the assay to any gene of interest is possible.
Furthermore, rapid detection of the exact genomic breakpoint-
positions opens the door to immediately identify patient specific
targets to trace fusion molecules within circulating tumor DNA
(ctDNA) from liquid biopsies and asses treatment responses by
monitoring of minimal residual disease.
A limitation of this approach is the requirement of non-
fragmented DNA. Applying the FUDGE crRNA protocol to FFPE
material (the current standard for pathology procedures), will
most likely fail to comprehensively identify fusion genes due to
short read lengths derived from degraded FFPE DNA. An
adaptation of the design strategy to regularly interspace crRNAs
at short intervals may overcome this issue; however, this
approach will drastically increase the assay costs per fusion gene.
Furthermore, intratumoral heterogeneity and tumor purity are
likely to influence the lower detection limits of our assay, and the
use of WGA in situations of low DNA availability may be useful
to accurately identify the breakpoint-location but only with prior
knowledge of both fusion gene partners. We set a cut-off of at
least two fusion-spanning reads to reliably detect a fusion gene
without further validation. In general, we observed a decrease in
on-target coverage for low throughput sequencing runs and/or
more distal breakpoint events (Supplementary Fig. 8), suggesting
that higher coverage of breakpoints can be obtained by guides
placed closer to breakpoints. Notably, none of the sequenced
DNA samples used in these experiments was specifically isolated
for long read sequencing. Thus, optimizing the isolation method
and therefore the length of the DNA molecules and/or incor-
porating the tiling approach will have a positive effect on
detecting these more distal events. Here, two fusions were only
detected with one fusion-spanning read each, requiring the
manual validation of the fusion gene by breakpoint PCR. How-
ever, by incorporating a multi-crRNA approach and increased
efforts from ONT to improve sequencing throughput, the per-
formance of FUDGE is expected to improve. In addition, the
latter would allow for higher capacities to multiplex samples,
reducing costs of the assay further.
Our current multiplexing approach, with sample pooling and
retrospective demultiplexing by breakpoint PCR, reduces cost but
prolongs assay duration and increases the complexity of sample
processing. With lower throughput flow cells, such as the ONT
Flongle, individual samples could be run separately, without
pooling and demultiplex-PCR, thus simplifying the workflow and
lowering assay costs dramatically.
Table 1 Comparison of DNA and RNA-based fusion gene detection methods.
DNA RNA
Stability Stable Instable
Breakpoint Across large genomic areas Only exon-exon junctions
Detection method FISH FUDGE Targeted-NGS WGS RT-PCR Targeted-NGS RNA seq
Speed (days) 1 2 7–14 7–14 1 7–14 7–14
Targeted Semi Semi Semi No Yes Semi No
Partner detection No Yes Yes Yes N/A Yes Yes
Promoter fusions No Yes Yes Yes No No No
Validation required N/A No No Yes (Sanger) No No Yes (Sanger)
MRD No Yes Yes Yes Yes Suboptimal Suboptimal
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In conclusion, FUDGE identifies fusion genes irrespective of
fusion partner or breakpoint-location from low-coverage nano-
pore sequencing. FUDGE overcomes various limitations of cur-
rent diagnostic assays by multiplexing targets in a rapid, accurate
assay and can be applied to detect fusion genes within 48 h. The
application of this assay in the clinic could allow for rapid gene
fusion detection to allow appropriate therapy initiation and
identification of specific genetic targets for blood-based minimal
residual disease tracing.
Methods
Cell lines and culture. Ewing sarcoma cell lines (A4573, CHP-100) and synovial
sarcoma cell line (HS-SYII) were cultured in 5% CO2 in a humidified atmosphere
at 37 °C in Dulbecco’s modified medium (DMEM) (Thermo Fisher) supplemented
with 10% fetal bovine serum (FBS) and antibiotics (100 U/ml penicillin and 100 μg/
ml streptomycin). The absence of Mycoplasma sp. contamination was determined
with a Lonza MycoAlert system. Cell lines were obtained in collaboration from
Anton Henssen, Charité Berlin.
ALL cell lines ALL-PO and KOPN8 and AML cell lines ML2 and Monomac-1
were maintained as suspension cultures in RPMI-1640 medium (Invitrogen),
supplemented with 10% or 20% fetal calf serum (FCS) and antibiotics. Cell lines
were obtained in collaboration from Ronald Stam, PMC Utrecht.
Patient material. The healthy donor (PP) provided written informed consent. The
patients ES1 and RH had been registered and treated according to German trial
protocols of the German Society of Pediatric Oncology and Hematology (GPOH).
This study was conducted in accordance with the Declaration of Helsinki and
Good Clinical Practice, and informed consent was obtained from all patients or
their guardians. Collection and use of patient specimen were approved by the
institutional review boards of Charité Universitätsmedizin Berlin. Specimen, clin-
ical data were archived and made available by Charité-Universitätsmedizin Berlin.
C1 and C2 were previously sequenced21 and were kindly provided by Prof
Ijzermans, Dept of Surgery, Erasmus Medical Center Rotterdam, The Netherlands.
B1 was a kind gift from Prof. dr. C.M. Zwaan, Erasmus Medical Center—Sophia
Children’s Hospital, Rotterdam, The Netherlands/Princess Maxima Center for
Pediatric Oncology, Utrecht, The Netherlands. Informed consent is given by the
patient or his/her parents or legal guardians, and all is performed in line with the
declaration of Helsinki, and the Erasmus MC—Sophia Children’s Hospital
approved the experiments.
CML, BL, ALL1, ALL2, and B2 were from the diagnostic sample archive of the
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. As the
work was interpreted as falling within the scope of diagnostic service improvement,
it did not require specific research ethics committee approval as stated in the EU
Clinical Trials Directive (2001/20/EC).
DNA Isolation. Genomic DNA from cultured cells (A4573, CHP-100 and HS-
SYII) and tissue (ES1 and RH) was extracted by using the column-based
NucleoSpin® Tissue DNA extraction kit (Macherey-Nagel) following manu-
facturer’s instructions. Sample quality control was performed using a 4200
TapeStation System (Agilent), and DNA content was measured with a Qubit 3.0
Fluorometer (Thermo Fisher).
Genomic DNA from the ALL cell lines (ALLPO and KOPN8), AML cell lines
(ML2 and Monomac-1) and AML patient (B1) was isolated by using the column-
based Qiagen DNeasy Blood and Tissue DNA extraction kit (Qiagen) following the
manufacturer’s instructions and DNA content was measured with a Qubit 2.0
Fluorometer (Thermo Fisher).
Genomic DNA was extracted either manually or with the QIAcube automated
sample processor with the AllPrep DNA/RNA mini kit for CML, BL, and ALL2
and the QIAamp blood mini kit for the samples ALL1 and B2.
WGA. For whole genome amplification (WGA), 10 ng starting material was
amplified with the repli-g mini kit (Qiagen) according to the manufacturer’s
protocol.
crRNA design. Each potential gene fusion constituted a known fusion partner to
be targeted with this enrichment technique, and an (un)known partner to be
identified following subsequent sequencing. The known target fusion partners were
designated as a 5′ or 3′ fusion partner, dependent upon known literature. Fur-
thermore, the most common breakpoint locations were extracted from a literature
search and the most distal breakpoint locations were noted as extreme borders of
the targeted area. If the unknown fusion partner was the 5′ partner, crRNAs were
designed as the sequence present on the minus strand of the gene (5′–>3′) until the
PAM sequence. If the unknown fusion partner was the 3′ partner, crRNAs were
designed as the sequence present on the plus strand of the gene (5′–>3′) until the
PAM sequence (Supplementary Fig. 1). Custom Alt-R® crRNAs were designed with
the Integrated DNA Technologies (IDT) custom gRNA design tool and chosen
with maximum on-target and lowest off-target scores (IDT).
Cas9 Enrichment and Nanopore Sequencing. Cas9 enrichment was adapted from
the ONT Cas9 enrichment protocol12. In brief, approximately 1 μg of genomic
DNA or WGA-DNA (Supplementary Data 1) was dephosphorylated with Quick
calf intestinal phosphatase (NEB) and CutSmart Buffer (NEB) for 10 min at 37 °C
and inactivated for 2 min at 80 °C. crRNAs were resuspended in TE pH7.5 to
100 μM. For simultaneous targeting of multiple loci, crRNAs were pooled equi-
molarly to 100 μM. Ribonucleoprotein complexes (RNPs) were prepared by mixing
100 uM equimolarialy pooled crRNA pools with 100 μM tracrRNA (IDT) and
duplex buffer (IDT), incubated for 5 min at 95 °C and thereafter cooled to room
temperature. 10 μM RNPs were mixed with 62 μM HiFiCas9 (IDT) and 1×
CutSMart buffer (NEB) and incubated at RT for 15 min to produce Cas9 RNPs.
Dephosphorylated DNA sample and Cas9 RNPs were mixed with 10 mM dATP
and Taq polymerase (NEB) at 37 °C for 15 min and 72 °C for 5 min to facilitate
cutting of the genomic DNA and dA-tailing. Adapter ligation mix was prepared by
mixing Ligation Buffer (SQK-LSK109, ONT), Next Quick T4 DNA Ligase (NEB)
and Adapter Mix (SQK-LSK109, ONT). The mix was carefully applied to the
processed DNA sample without vortexing and incubated at room temperature for
25 min. DNA was washed and bound to beads by adding TE pH8.0 and 0.3×
volume AMPure XP beads (Agencourt) and incubated for 10 min at room tem-
perature. Fragments below 3 kb were washed away by washing the bead-bound
solution twice with Long Fragment Buffer (SQK-LSK109, ONT). Enriched library
was released from the beads with Elution Buffer (SQK-LSK109, ONT). Enriched
library concentration was measured with a Qubit Fluorometer 3.0 (Thermo Fisher).
The library from one tumor sample was loaded onto one flow cell (R 9.4, ONT)
according to the manufacturer’s protocol. Sequencing was performed on a
GridION X5 instrument (ONT) and basecalling was performed by Guppy (ONT).
NanoFG. NanoFG can be found at https://github.com/SdeBlank/NanoFG.
Reads were mapped to the human reference genome version GRCHh37 by
using minimap2 (v. 2.6)26 with parameters: ‘-x map-ont -a’. The produced SAM file
was compressed to bam format and indexed with samtools (v. 1.7)27. Next,
structural variations were detected from the bam file. The user can choose either
NanoSV (v. 1.2.4)10 with default parameters: ‘min_mapq=12, depth_support=
False, mapq_flag=48’, cluster_distance=100, ci_flag=300’ or Sniffles (v.1.0.9)28
with default parameters: ‘-s 2 -n -1 --genotype’ to detect SVs. We here used
NanoSV for all experiments (except multiplexing). For the samples C1 and HS-
SYII, additional parameters: ‘cluster_count=1’ were used for NanoSV due to the
low number of reads spanning the fusion. For the multiplexing experiment, the
fraction of reads supporting the fusions was below the allele frequency cut-off in
NanoSV. Therefore, the default Sniffles settings were used to detect 6 fusions. By
default, all SVs that do not pass the built-in NanoSV or Sniffles filters are removed.
In addition, all insertions are also removed from the VCF.
NanoFG selected candidate SVs that possibly form a fusion gene by annotating
both ends of an SV with genes from the ENSEMBL database29. If both ends of the
SV are positioned in different genes it was flagged as a possible fusion. Next, all the
reads supporting the candidate SVs were extracted with samtools (v. 1.7)27.
To remap and accurately detect SVs, all reads extracted per candidate fusion
gene were re-mapped using LAST30 (921) with default settings for increased
mapping accuracy. Then, NanoSV was used to accurately define the breakpoints in
the remapped fusion candidates. NanoSV parameters ‘cluster_count=2,
depth_support=False’, cluster_distance=100, ci_flag=300’ were used to detect all
present fusions. For C1 and HS-SYII, ‘cluster_count=1’ was used as a parameter
for NanoSV.
To check and flag fusions, additional information from the ENSEMBL database
was gathered to produce an exact composition of the fusion gene. Only fusions that
have the ability to produce a continuous transcript on the same strand were
retained and additional flags were added to the sample to give extra indication if
reported fusions are likely important or if some information from the ENSEMBL
database is incomplete.
All gathered ENSEMBL gene information was used to produce an overview of
the detected fusions. This includes the genes involved, the exon or intron
containing the breakpoint, the exact position of the fusion, the number of fusion-
supporting reads, involved CDS length of both fused genes and the final fused CDS
length. The detected fusions were also reported in VCF format for further analysis.
The number of fusion-supporting reads in the overview can differ from the number
of reads reported in the vcf due to the fact that a read which supports a breakpoint
multiple times in NanoSV is detected as a single supporting read by NanoFG. To
give a better overview of detected fusions, NanoFG also produced a visual overview
in PDF format. Apart from information on the genes, flags, position and fusion
supporting reads it also included the locations of protein domains to provide quick
insight into what domain are involved in the fusion.
NanoFG automatically designed primers for fusion gene validation using
primer3 (ref. 31) with default settings, aiming for a 200–400 bp product. Table 2
contains all primer sequences used for validation of breakpoints.
The run time of NanoFG on +−25000 nanopore reads is approximately 20 min
using a single thread. Detailed instructions including a test-set can be found on
GitHub (https://github.com/SdeBlank/NanoFG).
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Minimal sequencing duration experiment. To detect differences in fusion gene
detection based upon sequencing duration, all fastqs were merged and all reads
were sorted based on the time of sequencing. The earliest time was taken as the
start of the sequencing run and subsequently reads were selected based on bins of 1,
2, 3, 4, 5, 6, 12, 18, 24, 30, 36, 42, and 48 h after the first read had been sequenced.
NanoFG was then run separately on every fastq by using default settings for every
sample. Using this approach, the time points where at least 2 supporting reads of a
fusion have been sequenced can be determined to define the minimal sequencing
duration necessary for each sample to produce two fusion-spanning reads.
Minimal supporting read cut-off. To select a minimum number of supporting
reads used in the detection of fusion genes, we ran NanoFG on a number of
samples (CHP-100, ES1, C1-WGA, and C2-WGA) with a minimum of one sup-
porting read. Thereafter, the number of fusions reported with a minimum of 1, 2, 3,
4, and 5+ supporting reads were counted.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Low coverage WGS Binary Alignment Map (BAM) files from nanopore sequencing are
available through controlled access at the European Genome-phenome Archive (EGA),
hosted at the EBI and the CRG (https://ega-archive.org), with accession number
EGAS00001003964. Requests for data access will be evaluated by the UMCU Department
of Genetics Data Access Board (EGAC00001000432) and transferred on completion of a
material transfer agreement and authorization by the medical ethical committee of the
UMCU to ensure compliance with the Dutch medical research involving human subjects
act. The source data underlying Figs. 2–7 are provided as a Source Data file. The
ENSEMBL database for genome build GRCh37 can be found at https://grch37.ensembl.
org/index.html. Any other relevant data are available from the authors upon reasonable
request. Source data are provided with this paper.
Code availability
NanoFG requirements, readme, and pipeline are at https://github.com/SdeBlank/
NanoFG. Source data are provided with this paper.
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